Navigo Proteins GmbH

Navigo Proteins discovers and develops novel scaffold proteins-based affinity ligands for commercial biologics GMP purification or as biopharmaceutical drugs/binders. They are all small, stable, highly engineerable, selective, and economically, homogeneously producible. In PRECISION CAPTURING a protein A-like scaffold serves for an antibody-like capture step even of non-Fc bearing molecules. In PRECISION TARGETING human ubiquitin is the basis for highly selective Affilin® ligands as part of a broad range of biopharmaceutical drugs. Navigo Proteins’ unique protein engineering expertise is the basis a world-wide unique, versatile scaffold proteins platform. Our robust, rapid and reliable high-throughput-based, robotics assisted platform designs, produces, analyzes and selects suitable affinity ligand proteins, optimized for their tasks in industrial downstream processing or as biopharmaceutical drugs. PRECISION CAPTURING creates custom ligands against any biologic, Fc-independent, and enables antibody-like affinity downstream processes, with competitive binding capacities, caustic stabilities, usage-cycles, flow rates and commercially available off-the-shelf leaching assays. It is applicable for purifying any recombinant protein, mAb, virus, VLP, cell, etc. Navigo Proteins has established partnerships worldwide to convert its custom affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing. Our PRECISION TARGETING platform creates tailored ligands which bind any desired biologic in biopharmaceutical or in diagnostic use, e.g. radiopharmaceuticals, Protein-drug-conjugates, CAR-T ligands or theranostics, in which the same Affilin® binder is employed in diagnosis, treatment and treatment-monitoring. Navigo Proteins is about 70 heads strong, steadily growing and based in Halle, S/W of Berlin. We offer our expertise to interested pharma, biotech and life sciences companies. https://www.navigo-proteins.com/imprint